ArticleLaboratory animal research2026
A streamlined approach for gene editing in non-obese diabetes (NOD) mice via CRISPR/Cas9.
Article in Laboratory animal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGene targeting via CRISPR/Cas9 has become a powerful tool to create animal models for human genetic disorders. Although CRISPR/Cas9 mediated gene editing is relatively simple, factors such as mouse strain, breeding performance, and quality and recovery of the embryos, can limit the overall outcome. Genetic manipulations are commonly carried out using embryos from a well characterized C57BL6 strain of mouse however, the ability for direct gene editing in strains such as non-obese diabetic (NOD) mice, which is an important strain to create mouse models for autoimmune type 1 diabetes (TD1), immunology, cancer and infectious diseases, is quite limiting. Therefore, gene modification in NOD mice in one way is carried out via a time-consuming cross breeding with the transgenic animals created in a more permissive C57BL6 strain for several generations which can take long time and consume valuable resources. Direct gene manipulation in the NOD mouse background will greatly expedite the creation of genetically engineered mouse models bypassing the complicated steps of backcrossing thus saving almost two years and valuable resources and help promoting 3 R principles of refinement of animal welfare.
resultsWe present improved and streamlined conditions for gene manipulation directly on the pure NOD background using embryos from NODShiLtJ mouse, a strain commonly used for studies on autoimmune TD1 and animal models for potential applications in cancer, immunology, and infectious disease research. High efficiency, 80-90% success rate, was achieved via CRISPR/Cas9 genome editing in pups born from embryos recovered from naturally mated 4-week-old NODShiLtJ females superovulated under specific time schedules.
conclusionsWe demonstrate that 4-week-old NODShiLtJ females superovulated and mated under specific time requirements can produce healthy and robust embryos for gene manipulation saving significant resources and maintenance costs that will help in 3R principles of refinement to improve animal welfare. Similar conditions may be applied to create new genetic modifications in complex NOD/SCID Gamma (NSG) and NOD/SCID Rag (NRG) mice for dissecting mechanisms of immunology as well as generation of mouse models for infectious diseases for underlying conditions in human patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.